Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination with the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRC
Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination with the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRC
Recruiting · NCT06126822 · Registry updated 2025-03-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination with the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRC | Ebola hemorrhagic fever, Filoviridae infectious disease, Infections, Mononegavirales infectious disease, RNA Virus Infections, viral hemorrhagic fever, viral infectious disease | Recruiting | Phase 3 | 2025-03-18 | NCT06126822 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Institut National pour la Recherche Biomedicale (INRB) | 3 |
| Institute of Tropical Medicine, Belgium | 29 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Institut National de Recherche Biomédicale (INRB) | Kinshasa | Democratic Republic of the Congo | 1 |
| Institut National de Recherche Biomédicale (INRB) | Goma | Democratic Republic of the Congo | 1 |